



Landmark 24-Month Data Show DOT™ Lenses Save More than 1D of Myopia Progression in Young Children

Two-Year Chinese Study Results From SightGlass Vision Affirm High Efficacy with Contrast Management

DALLAS, May 6, 2026—[SightGlass Vision](#) has announced new clinical data showing that its DOT™ spectacle lenses for myopia control saved more than 1D of progression on average after two years in Chinese children aged 6 to 10.^{1††} The findings build on previously reported 12-month CATHAY study data and affirm that DOT lenses with contrast management deliver strong and consistent efficacy in children.

Across the full study population of patients in China aged 6 to 13, the lenses slowed average myopia progression by 0.78D and average axial length progression by 0.40 mm after two years of wear versus the control group.^{1*} The findings of 0.78D represent a 67% reduction in progression, and 0.40 mm represents a 62% reduction in axial length.^{1*} The full study population findings were presented by Jennifer Hill in “Control of Myopia Using Contrast Modulation Spectacle Lenses in a Chinese Population: 24-Month Results” at the [ARVO 2026 Annual Meeting](#), the global forum for the ophthalmology, optometry, and ocular science communities.

“Our CATHAY two-year results add to the robust data that establishes DOT lenses as a high-efficacy, non-defocus spectacle solution crucial for practices engaged in myopia management to complete their portfolio,” said Andrew Sedgwick, chief executive officer of SightGlass Vision. “The strength of the outcomes, particularly in younger children, reinforces the importance of early intervention.”

Unlike defocus-based solutions, DOT lenses are specifically designed to reduce retinal contrast signaling through the incorporation of light scattering elements.² The CATHAY two-year results supplement the sizable body of clinical research that supports DOT lenses’ contrast management approach for myopia control.

Additional findings from the full study population showed that 59% of DOT lens wearers had 0.50D or less myopia progression after two years, compared with 19% of children in the control group.^{1**} The differences were statistically significant ($p < 0.0001$).^{1**}

Building on its four-year North American CYPRESS study, SightGlass Vision initiated the CATHAY trial to compare DOT lenses with conventional single vision lenses and to evaluate their continued safety and efficacy in Chinese children across five clinical sites in China. A total of 172 myopic children aged 6 to 13 completed the second year of the study.

“The breadth of clinical research now available demonstrates why practitioners should adopt DOT lenses as a treatment strategy for myopia control,” said David Webley, senior director, clinical, medical, and professional affairs at SightGlass Vision. “The strong efficacy results from the CATHAY study continue to validate that contrast management, with DOT lenses, is an effective tool in the fight against the myopia epidemic.”

Other research presented at ARVO 2026 further expanded the understanding of DOT lens performance and wearer experience. “Pupil Size Effect on Myopia Progression with Contrast Modulation Spectacle Lenses” (Webley D, et al.) found no significant association between pupil size and the rate of myopia progression in children wearing DOT lenses at 12 months. In addition, “Viewing Behavior with Contrast Modulation Spectacle Lenses” (Kollbaum P, et al.) showed that children exhibited similar viewing behavior when wearing both DOT lenses and single vision lenses across a range of daily activities, suggesting good visual performance across the lens, in line with previous studies.

SightGlass Vision’s DOT lenses have made their commercial debut in China, Canada, Israel, Spain, and the U.K. Founded in 2016, the company now operates as a joint venture of CooperVision, Inc. and Essilor International.

For more information, visit SightGlassVision.com.

###

About SightGlass Vision

SightGlass Vision™ develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics

Technology™ is based on landmark discoveries surrounding myopia progression. DOT™ spectacle lenses using its patent-protected approach incorporate thousands of light-scattering elements designed to mimic more natural contrast on the retina. DOT™ lenses provide myopia control through contrast management and have proven results from Gold-standard clinical trials in North America and China. Founded in 2016, the company now operates as a joint venture of CooperVision, Inc. and Essilor International to accelerate commercialization opportunities and expand the myopia management category worldwide.

**Prescribed DOT lens wear time was 10 hours per day.*

†LS mean progression difference of 1.01D between test and control groups.

‡ For $\leq 0.50D$, control group = 19%; the differences were significant $p < 0.0001$.

SightGlass Vision™ products are not available for sale in all countries, including the United States.

Diffusion Optics Technology and DOT are trade marks of SightGlass Vision, Inc. © 2026 SightGlass Vision, Inc. All Rights Reserved.

Media Contact

Carson Daniels, Senior Counselor

McDougall Communications for SightGlass Vision

+1-315-427-6394 or carson@mcdougallpr.com

^[1] SGV data on file 2026. Control of myopia using contrast modulation spectacle lenses in a Chinese population (n = 172, 5 sites in China). Overall study patient population aged 6–13 years. The clinical trial was designed to compare DOT lenses with conventional single-vision lenses to evaluate their continued safety and efficacy in Chinese children.

^[2] Rappon et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). Br J Ophthalmol. 2023;107(11):1709–1715.